{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T23:38:39Z","timestamp":1769297919582,"version":"3.49.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.neuropharm.2014.07.017","type":"journal-article","created":{"date-parts":[[2014,8,5]],"date-time":"2014-08-05T19:45:16Z","timestamp":1407267916000},"page":"259-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Mapping the binding pocket of a novel, high-affinity, slow dissociating tachykinin NK3 receptor antagonist: Biochemical and electrophysiological characterization"],"prefix":"10.1016","volume":"86","author":[{"given":"Pari","family":"Malherbe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Knoflach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Marcuz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Bohnert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henner","family":"Knust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasane","family":"Ratni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Will","family":"Spooren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa M.","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Bissantz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2014.07.017_bib1","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1517\/13543776.14.10.1421","article-title":"Neurokinin antagonists and their potential role in treating depression and other stress disorders","volume":"14","author":"Albert","year":"2004","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib2","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.2174\/0929867043364748","article-title":"Tachykinins and tachykinin receptors: structure and activity relationships","volume":"11","author":"Almeida","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib3","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1460-9568.1996.tb01265.x","article-title":"Evidence for modulation of dopamine-neuronal function by tachykinin NK3 receptor stimulation in gerbil mesencephalic cell cultures","volume":"8","author":"Alonso","year":"1996","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib4","doi-asserted-by":"crossref","first-page":"D115","DOI":"10.1093\/nar\/gkh131","article-title":"UniProt: the universal protein knowledge base","volume":"32","author":"Apweiler","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib5","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1043-9471(05)80049-7","article-title":"Integrated methods for construction three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors","volume":"25","author":"Ballesteros","year":"1995","journal-title":"Methods Neurosci."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0304-3940(01)01685-8","article-title":"Expression of tachykinin NK2 receptor mRNA in human brain","volume":"303","author":"Bensaid","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib7","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1021\/jm2017072","article-title":"Identification of a crucial amino acid in the Helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK(1)\/NK(3) antagonists","volume":"55","author":"Bissantz","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib8","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0006-8993(97)01062-7","article-title":"Mesencephalic dopaminergic neurons expressing neuromedin K receptor (NK3): a double immunocytochemical study in the rat","volume":"780","author":"Chen","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib9","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1126\/science.1150577","article-title":"High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor","volume":"318","author":"Cherezov","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2014.07.017_bib10","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1126\/science.1197410","article-title":"Structure of the human dopamine D3 receptor in complex with a D2\/D3 selective antagonist","volume":"330","author":"Chien","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2014.07.017_bib11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0026-895X(25)10525-7","article-title":"Two classes of structurally different antagonists display similar species preference for the human tachykinin neurokinin3 receptor","volume":"48","author":"Chung","year":"1995","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib12","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1038\/sj.npp.1301549","article-title":"In\u00a0vitro and in\u00a0vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia","volume":"33","author":"Dawson","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2014.07.017_bib13","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2174\/138161210790170067","article-title":"Therapeutic utility of NK3 receptor antagonists for the treatment of schizophrenia","volume":"16","author":"Dawson","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib14","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2174\/138161209788168074","article-title":"Tachykinin receptors as therapeutic targets in stress-related disorders","volume":"15","author":"Ebner","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib15","first-page":"717","article-title":"Talnetant GlaxoSmithKline","volume":"6","author":"Evangelista","year":"2005","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.neuropharm.2014.07.017_bib16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1568014033483789","article-title":"Role of peripheral tachykinin receptors in neurogenic inflammation of the respiratory, genitourinary and gastrointestinal systems","volume":"2","author":"Evangelista","year":"2003","journal-title":"Curr. Med. Chem. Anti Inflamm. Anti Allergy Agents"},{"key":"10.1016\/j.neuropharm.2014.07.017_bib17","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1523\/JNEUROSCI.09-10-03463.1989","article-title":"Morphology and electrophysiological properties of immunocytochemically identified rat dopamine neurons recorded in\u00a0vitro","volume":"9","author":"Grace","year":"1989","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib18","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/brain\/122.4.593","article-title":"The neuropathology of schizophrenia. A critical review of the data and their interpretation","volume":"122","author":"Harrison","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2014.07.017_bib19","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0960-894X(98)00215-7","article-title":"High affinity, selective neurokinin 2 and neurokinin 3 receptor antagonists from a common structural template","volume":"8","author":"Harrison","year":"1998","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib20","doi-asserted-by":"crossref","first-page":"10915","DOI":"10.1073\/pnas.89.22.10915","article-title":"Amino acid substitution matrices from protein blocks","volume":"89","author":"Henikoff","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib21","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1021\/cn100061r","article-title":"ACS chemical neuroscience molecule spotlight on saredutant","volume":"1","author":"Hopkins","year":"2010","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib22","doi-asserted-by":"crossref","first-page":"10048","DOI":"10.1021\/bi00031a029","article-title":"Identification of residues involved in ligand binding to the neurokinin-2 receptor","volume":"34","author":"Huang","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2014.07.017_bib23","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1126\/science.1164772","article-title":"The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist","volume":"322","author":"Jaakola","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2014.07.017_bib24","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1124\/jpet.106.107375","article-title":"Determining the potency and molecular mechanism of action of insurmountable antagonists","volume":"319","author":"Kenakin","year":"2006","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib25","unstructured":"Knust, H., Koblet, A., Nettekoven, M., Ratni, H., Riemer, C., Vifian, W., 2011. Pyrrolidine derivatives as NK-3 receptor, WO 2011\/073160."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib26","doi-asserted-by":"crossref","first-page":"37944","DOI":"10.1074\/jbc.M106330200","article-title":"Interaction of Met297 in the seventh transmembrane segment of the tachykinin NK2 receptor with neurokinin A","volume":"276","author":"Labrou","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib27","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0895-7061(99)00142-9","volume":"12","author":"Lacourciere","year":"1999","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib28","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0028-3908(00)00149-0","article-title":"Detailed distribution of neurokinin 3 receptors in the rat, guinea pig and gerbil brain: a comparative autoradiographic study","volume":"40","author":"Langlois","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2014.07.017_bib29","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1517\/14728222.7.3.343","article-title":"Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases","volume":"7","author":"Lecci","year":"2003","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.neuropharm.2014.07.017_bib30","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.bcp.2009.01.020","article-title":"Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3","volume":"77","author":"Leffler","year":"2009","journal-title":"Biochem Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib31","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.neuroscience.2006.10.058","article-title":"Predominant surface distribution of neurokinin-3 receptors in non-dopaminergic dendrites in the rat substantia nigra and ventral tegmental area","volume":"144","author":"Lessard","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2014.07.017_bib32","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(03)13306-5","article-title":"New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis","volume":"361","author":"Leucht","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2014.07.017_bib33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0269881108094524","article-title":"Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol","volume":"24","author":"Liem-Moolenaar","year":"2010","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib34","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pbb.2007.10.020","article-title":"Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models","volume":"89","author":"Louis","year":"2008","journal-title":"Pharmacol. Biochem Behav."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib35","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1124\/mol.107.042754","article-title":"Me-talnetant and osanetant interact within overlapping but not identical binding pockets in the human tachykinin neurokinin 3 receptor transmembrane domains","volume":"73","author":"Malherbe","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib36","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1021\/jm900948q","article-title":"Identification of a critical residue in the transmembrane domain 2 of tachykinin neurokinin 3 receptor affecting the dissociation kinetics and antagonism mode of osanetant (SR 142801) and piperidine-based structures","volume":"52","author":"Malherbe","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib37","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0143-4179(98)90075-0","article-title":"Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: an in\u00a0vivo microdialysis approach in guinea pig","volume":"32","author":"Marco","year":"1998","journal-title":"Neuropeptides"},{"key":"10.1016\/j.neuropharm.2014.07.017_bib38","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ddstr.2006.11.013","article-title":"NK3 receptor antagonists for the treatment of schizophrenia","volume":"3","author":"Meltzer","year":"2006","journal-title":"Drug. Discov. Today Ther. Strat."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib39","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","article-title":"Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder","volume":"161","author":"Meltzer","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.07.017_bib40","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.pbb.2008.04.003","article-title":"Behavioral effects of saredutant, a tachykinin NK2 receptor antagonist, in experimental models of mood disorders under basal and stress-related conditions","volume":"90","author":"Micale","year":"2008","journal-title":"Pharmacol. Biochem Behav."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neulet.2011.07.057","article-title":"Distribution and pharmacological characterization of primate NK-2 tachykinin receptor in the central nervous system of the rhesus monkey","volume":"503","author":"Nagano","year":"2011","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib42","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0306-4522(96)00625-2","article-title":"Tachykinin neurokinin-1 and neurokinin-3 receptor-mediated responses in guinea-pig substantia nigra: an in\u00a0vitro electrophysiological study","volume":"78","author":"Nalivaiko","year":"1997","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2014.07.017_bib43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejphar.2008.10.011","article-title":"The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils","volume":"600","author":"Nordquist","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib44","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.289.5480.739","article-title":"Crystal structure of rhodopsin: a G protein-coupled receptor","volume":"289","author":"Palczewski","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2014.07.017_bib45","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1517\/13543780903379530","article-title":"Tachykinin receptor antagonists in clinical trials","volume":"18","author":"Quartara","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.neuropharm.2014.07.017_bib46","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/cne.20664","article-title":"Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain","volume":"490","author":"Rigby","year":"2005","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib47","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1126\/science.1150609","article-title":"GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function","volume":"318","author":"Rosenbaum","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2014.07.017_bib48","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0306-4522(02)00748-0","article-title":"Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites","volume":"116","author":"Saffroy","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2014.07.017_bib49","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0022-3565(24)36725-4","article-title":"Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist","volume":"281","author":"Sarau","year":"1997","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib50","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1124\/pr.54.2.285","article-title":"The tachykinin peptide family","volume":"54","author":"Severini","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib51","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.brainres.2010.08.087","article-title":"Impact of mutations in kisspeptin and neurokinin B signaling pathways on human reproduction","volume":"1364","author":"Silveira","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib52","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nrd1905","article-title":"Opinion: NK3 receptor antagonists: the next generation of antipsychotics?","volume":"4","author":"Spooren","year":"2005","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib53","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0022-3565(24)29250-8","article-title":"Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function","volume":"299","author":"Steinberg","year":"2001","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0006-8993(94)90052-3","article-title":"Localization of striatal and nigral tachykinin receptors in the rat","volume":"646","author":"Stoessl","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib55","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrd1500","article-title":"Biochemical mechanisms of drug action: what does it take for success?","volume":"3","author":"Swinney","year":"2004","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib56","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ng.306","article-title":"TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction","volume":"41","author":"Topaloglu","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib57","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1046\/j.1472-8206.2002.00095.x","article-title":"New insights in insurmountable antagonism","volume":"16","author":"Vauquelin","year":"2002","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib58","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/syn.20908","article-title":"NK3 receptors mediate an increase in firing rate of midbrain dopamine neurons of the rat and the guinea pig","volume":"65","author":"Werkman","year":"2011","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2014.07.017_bib59","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1006\/bbrc.1994.1137","article-title":"Identification of methionine134 and alanine146 in the second transmembrane segment of the human tachykinin NK3 receptor as reduces involved in species-selective binding to SR 48968","volume":"198","author":"Wu","year":"1994","journal-title":"Biochem Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2014.07.017_bib60","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1126\/science.1202793","article-title":"Structure of an agonist-bound human A2A adenosine receptor","volume":"332","author":"Xu","year":"2011","journal-title":"Science"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814002792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814002792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:48:04Z","timestamp":1758437284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390814002792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":60,"alternative-id":["S0028390814002792"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.07.017","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mapping the binding pocket of a novel, high-affinity, slow dissociating tachykinin NK3 receptor antagonist: Biochemical and electrophysiological characterization","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}